Clinical Trial

A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-26; most recent amendment 2025-12-11.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT07003321
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Solid Tumor
Enrollment 120 participants
Start Date 2025-09-12
Primary Completion 2027-09 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-18